Psychiatric History and Overactive Bladder Symptom Severity in Ambulatory Urogynecological Patients.
overactive bladder
psychiatric comorbidity
psychotropic medication
urinary incontinence
urogynecology
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
03 Sep 2021
03 Sep 2021
Historique:
received:
04
08
2021
revised:
27
08
2021
accepted:
31
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
A link between psychiatric comorbidities and overactive bladder symptomatology has been suggested by preclinical and clinical studies. Given this, we hypothesized that a psychiatric history and current treatment with psychotropic medications could be related to the severity of overactive bladder and incontinence symptoms in patients referred to a tertiary care urogynecological center. One hundred and twenty-seven female patients diagnosed with an overactive bladder were screened for a lifetime history of psychiatric disorders and the type and number of psychotropic medications currently taken. The overall severity of overactive bladder symptoms was assessed using the Indevus Urgency Severity Scale. The severity and impact of urinary incontinence on the quality of life were quantified with the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form. Urinary incontinence was further quantified with the aid of the Urinary Distress Inventory-6. The patients were screened for stress urinary incontinence using the Stamey Incontinence Score. A psychiatric history, as well as current use of at least two psychotropic medications, was associated with increased severity of overactive bladder symptoms. A history of depression and current treatment with any selective serotonin reuptake inhibitor was associated with increased severity of stress urinary incontinence symptoms. Current treatment with other psychotropic medications, including sedative-hypnotics and drugs with anticholinergic properties was not related to the severity of overactive bladder and incontinence symptoms.
Identifiants
pubmed: 34501436
pii: jcm10173988
doi: 10.3390/jcm10173988
pmc: PMC8432447
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neurourol Urodyn. 1995;14(2):131-9
pubmed: 7780440
Int Urogynecol J. 2017 Jul;28(7):1033-1039
pubmed: 27942790
J Clin Psychiatry. 2005;66 Suppl 7:5-13
pubmed: 16124836
Neurourol Urodyn. 2009;28(4):287
pubmed: 19350662
Int Urogynecol J. 2018 Jul;29(7):987-995
pubmed: 28762178
Int Urogynecol J. 2012 Mar;23(3):299-306
pubmed: 22068320
J Pharmacol Exp Ther. 2006 Jan;316(1):129-35
pubmed: 16166271
Eur Urol. 2019 Jan;75(1):129-168
pubmed: 30293906
J Urol. 2005 May;173(5):1805-11
pubmed: 15821592
J Urol. 2006 Mar;175(3 Pt 1):1063-6; discussion 1066
pubmed: 16469618
J Urol. 2005 Aug;174(2):604-7
pubmed: 16006914
BJU Int. 2020 May;125(5):709-717
pubmed: 31991511
Neurourol Urodyn. 2012 Jun;31(5):652-8
pubmed: 22473921
Neurourol Urodyn. 2019 Feb;38(2):525-534
pubmed: 30575999
J Urol. 2019 Sep;202(3):558-563
pubmed: 31039103
Respir Med. 2018 Feb;135:35-41
pubmed: 29414451
Am J Obstet Gynecol. 2007 Jul;197(1):82.e1-4
pubmed: 17618768
Br J Health Psychol. 2006 Sep;11(Pt 3):463-82
pubmed: 16870056
BMC Psychiatry. 2020 Nov 2;20(1):521
pubmed: 33138789
World Psychiatry. 2010 Oct;9(3):131-44
pubmed: 20975855
Neurourol Urodyn. 2014 Jun;33(5):622-4
pubmed: 24838519
Neurourol Urodyn. 2010 Apr;29(4):587-91
pubmed: 19760758
Front Neurosci. 2019 Jun 13;13:535
pubmed: 31263396
Am J Obstet Gynecol. 1996 Jul;175(1):10-7
pubmed: 8694033
Ann Pharmacother. 2016 Jun;50(6):471-4
pubmed: 27005574
BMC Psychiatry. 2019 Apr 24;19(1):122
pubmed: 31014311
Qual Life Res. 1994 Oct;3(5):291-306
pubmed: 7841963
Int Urogynecol J. 2010 Jan;21(1):5-26
pubmed: 19937315
Int Urogynecol J. 2013 Dec;24(12):2087-92
pubmed: 23749240
BJU Int. 2011 Nov;108(9):1459-71
pubmed: 21371240
Br Med J (Clin Res Ed). 1986 Mar 8;292(6521):651-3
pubmed: 3081209
Br J Pharmacol. 2014 Feb;171(4):995-1006
pubmed: 24224799
Neurourol Urodyn. 2018 Jan;37(1):223-228
pubmed: 28407347
Neurourol Urodyn. 2018 Jun;37(5):1849-1855
pubmed: 29926966
Neurourol Urodyn. 2020 Jul;39 Suppl 3:S70-S79
pubmed: 32662559
PLoS One. 2018 Mar 21;13(3):e0193635
pubmed: 29561858
Neurourol Urodyn. 2020 Feb;39(2):650-657
pubmed: 31774204
Eur J Obstet Gynecol Reprod Biol. 2017 Aug;215:171-174
pubmed: 28633095
J Psychosom Res. 2015 Feb;78(2):95-108
pubmed: 25499886
Surg Gynecol Obstet. 1973 Apr;136(4):547-54
pubmed: 4570309
Pharmacol Rev. 2004 Dec;56(4):581-631
pubmed: 15602011
Psychiatry Res. 2020 Jun;288:112993
pubmed: 32334277
Neurourol Urodyn. 2019 Jan;38(1):22-30
pubmed: 30350884
Int Urogynecol J. 2021 Jan;32(1):103-109
pubmed: 32095954
Neurourol Urodyn. 2016 Nov;35(8):902-907
pubmed: 26227539
Eur Urol. 2019 Jun;75(6):988-1000
pubmed: 30922690
Am J Obstet Gynecol. 2017 Oct;217(4):430.e1-430.e8
pubmed: 28645572
Front Psychiatry. 2017 Nov 09;8:215
pubmed: 29170645
Cancer Med. 2020 Jun;9(12):4395-4404
pubmed: 32301251